JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Artificial Intelligence and Machine Learning for Accelerated Drug Discovery and Development

Abhishek Pathak*[1], Usha Vishwakarma[2], Gulfisha Shaikh[3], Sapna Malviya[4], Anil Kharia[5]

[1] *UG Scholar, Department of Pharmacy, Modern Institute of Pharmaceutical Sciences, Indore, Madhya Pradesh, India*
[2] *Associate Professor, Department of Pharmacology, Modern Institute of Pharmaceutical Sciences Indore, Madhya Pradesh, India*
[3] *Associate Professor, Department of Pharmaceutics, Modern Institute of Pharmaceutical Sciences Indore, Madhya Pradesh, India*
[4] *Professor and Head of Institute, Department of Pharmacognosy, Modern Institute of Pharmaceutical Sciences Indore, Madhya Pradesh, India*
[5] *Professor and Principal, Department of Pharmaceutical Chemistry, Modern Institute of Pharmaceutical Sciences Indore, Madhya Pradesh, India*

Publication history: Received on 6th December 2025; Revised on 18th January 2026; Accepted on 20th January 2026

Article DOI: 10.69613/vnt8nx21

Abstract: Traditional drug discovery is a protracted and resource-intensive endeavor, often spanning over a decade with substantial financial requirements and high attrition rates in clinical phases. Artificial intelligence and machine learning algorithms offer a robust foundation for streamlining these processes by facilitating the analysis of vast chemical libraries and biological datasets. In target identification, deep learning architectures enable the prediction of protein-ligand interactions with high precision, while high-throughput screening data analysis identifies viable drug candidates more efficiently than conventional methods. Beyond early-stage discovery, computational models play a critical role in predicting Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiles, thereby mitigating the risk of late-stage failures. The emergence of personalized medicine further benefits from these technologies through the integration of genomic profiles and clinical histories to tailor therapeutic interventions for specific patient cohorts. However, significant barriers persist, including the requirement for high-quality, reproducible datasets and the substantial environmental footprint associated with training large-scale models. Overcoming these limitations through collaborative, multidisciplinary approaches is essential for the full realization of automated pharmaceutical development. The transition toward an AI-driven paradigm promises to enhance the efficacy, safety, and cost-effectiveness of novel therapeutics, ultimately improving global public health outcomes.

Keywords: Artificial Intelligence; Machine Learning; Drug Design; Personalized Medicine; ADMET Prediction.

1. Introduction

Pharmaceutical research is a high-risk, high-reward environment where the journey from initial molecule identification to market approval often exceeds ten years [1]. Historically, the drug development pipeline has struggled with diminishing returns, a phenomenon frequently attributed to the increasing complexity of biological targets and the stringent regulatory requirements for safety and efficacy. Each developmental stage presents significant hurdles, and the vast majority of candidate molecules fail to reach the market, rendering the traditional model both expensive and inefficient [2, 3]. The industry is now seeking innovative technological solutions to mitigate these risks and enhance the productivity of research and development programs.

In the current era, the integration of artificial intelligence (AI) has emerged as a primary strategy for managing the data-heavy nature of modern pharmacology. Drug discovery necessitates the screening of millions of chemical compounds against diverse biological markers, a task that exceeds the capacity of manual laboratory techniques. Machine learning (ML) provides a computational shortcut by identifying patterns within high-throughput screening data and predicting the bioactivity of novel scaffolds [4, 5]. The pharmaceutical sector, which was once criticized for its slow adoption of mechanical and digital innovations, is now at the forefront of implementing advanced engineering principles to facilitate the creation of human medications [6, 7].

Recent advancements in digitalization have allowed for the storage of massive amounts of biological and chemical data in public repositories such as ChEMBL and PubChem. These datasets serve as the training ground for predictive models that target complex pathogens, including recent efforts in developing therapeutics for severe acute respiratory syndrome coronavirus 2 [8, 9]. Computational platforms like DeepTox and MoleculeNet have demonstrated that toxicity can be evaluated with high accuracy before a single animal study is performed, showing the potential for AI to reform the ethical and financial foundations of the industry [10, 11].

* Corresponding author: Abhishek Pathak



Figure 1. AI-Assisted Drug Discovery Process

2. Computational Intelligence in Drug Discovery

2.1. The Evolution of AI Architectures in Pharmaceuticals

The recent shift in pharmaceutical research is defined by the application of enhanced computational power to solve clinical issues that were previously considered intractable. AI architectures are no longer peripheral tools but are central to the drug development pipeline, from preclinical optimization to the refinement of clinical trial designs [12, 13]. The digitalization of information within the industry has created a scenario where the volume of data generated by genomic sequencing and proteomic analysis is too vast for human interpretation alone. AI systems manage this complexity through automated workflows that integrate disparate data streams into cohesive predictive models [14, 15].

2.2. Core Methods of Machine Learning

Machine learning is a subset of AI that focuses on the development of algorithms capable of learning from and making predictions on data. In the context of drug discovery, these techniques are categorized into supervised, unsupervised, and reinforcement learning. Large pharmaceutical companies have increasingly invested in these technologies to minimize the reliance on live animal testing and to reduce the labor-intensive nature of lead optimization [16, 17]. The effectiveness of these models relies heavily on the quality of biological features provided during the training phase, such as cellular toxicity markers, pharmacokinetic endpoints, and cytochrome P450 inhibition values [18, 19].

Figure 2. The Active Learning Cycle in Model Refinement

Table 1. Machine Learning Methods and Their Applications

Learning Paradigm	Common Algorithms	Applications in Drug Discovery
Supervised Learning	Support Vector Machines (SVM), Random Forest, Neural Networks	Quantitative Structure-Activity Relationship (QSAR) modeling and bioactivity prediction.
Unsupervised Learning	K-means Clustering, Principal Component Analysis (PCA)	Identifying novel molecular scaffolds and clustering compounds by structural similarity.
Deep Learning	Convolutional Neural Networks (CNN), Recurrent Neural Networks (RNN)	Analysis of protein-ligand 3D structures and molecular sequence generation.
Reinforcement Learning	Generative Adversarial Networks (GANs)	De-novo drug design by rewarding the generation of molecules with specific properties.

The implementation of machine learning in pharmaceutical manufacturing and design follows a cyclical process known as active learning. This methodology involves the selection of specific data subsets to train an algorithm, which then generates results that are tested through experimental validation. The discrepancy between predicted and observed results is then fed back into the system to refine the selection functions and computational parameters [20, 21]. This iterative approach ensures that the model becomes increasingly reliable over time, eventually reaching a stage of accuracy that allows for the manufacturing of optimized drug candidates with minimal experimental oversight.

2.3. Integration of Molecular Libraries and Databases

The success of any AI-driven approach is contingent upon the availability of machine-readable data. Public chemical libraries contain information on millions of molecules, providing a foundational resource for building drug discovery models. These libraries allow researchers to perform virtual screenings that match small molecules to specific disease targets, effectively narrowing the chemical space from billions of possibilities to a manageable number of high-potential leads [22, 23]. Computational groups can generate a deeper understanding of the structure-activity relationships that govern drug-target interactions by utilizing these databases, which is essential for the design of the next generation of therapeutics [24, 25].

Table 2. Public Databases for Virtual Screening

Database	Primary Content Type	Approximate Size	Utility
ChEMBL	Bioactive molecules with drug-like properties	> 2 million compounds	Mapping molecules to biological targets and recording assay results.
PubChem	General chemical substances and biological activities	> 110 million compounds	Searching for chemical structures and physical property data.
ZINC15	Commercially available compounds for docking	> 230 million compounds	Providing ready-to-dock 3D formats for virtual high-throughput screening.
DrugBank	Comprehensive drug and target information	> 14,000 entries	Essential resource for drug repurposing and interaction analysis.

Both cohorts received standard physiotherapy alongside their specific sensory training. This included stretching of major muscle groups, lower limb strengthening, basic gait re-education, and breathing exercises. This ensured that all participants received a baseline level of evidence-based care while allowing for the evaluation of the additional sensory-specific interventions.

2.4. Statistical Tests

Data were processed using statistical software, with the Shapiro–Wilk test applied to verify the normality of the distribution. For within-group comparisons of pre- and post-intervention scores, paired t-tests were employed. Independent t-tests were used to analyze the differences in improvement scores between Group A and Group B. A p-value of less than 0.05 was considered statistically significant for all tests

3. Artificial Intelligence for Target Identification

The initial phase of the drug discovery process involves the identification of biological targets, typically proteins or nucleic acids, that play a pivotal role in disease progression. AI-driven methodologies have significantly enhanced this stage by enabling the systematic screening of small molecule databases to find candidates that exhibit specific bioactivity against these targets [26]. Computational docking software facilitates the exploration of molecular interactions at an atomic level, allowing researchers to

evaluate how potential leads bind to target sites. The use of molecular analogues provides a baseline for developing novel compounds with improved efficacy and reduced side effects [27].

3.1. High-Throughput Screening

High-throughput screening serves as a primary mechanism for isolating potential molecules from vast chemical libraries for further experimental analysis. The integration of AI into this workflow allows for the rapid identification of molecules that are most applicable to a specific health condition, while simultaneously evaluating their stability and potential for off-target interactions [28]. Various statistical and machine learning methods, such as neural networks, multiple linear regression, and decision trees, are employed to analyze the complex datasets generated during these screenings [29]. Quality control measures, including the analysis of variance, ensure that the data remains robust and that the identified hits possess the necessary characteristics for downstream development [30].

3.2. Biomarker Discovery and Validation

In the contemporary landscape of molecular medicine, the discovery of reliable biomarkers is essential for validating drug targets and monitoring therapeutic responses. Biomarker discovery requires the collection and analysis of extensive sample sets to identify markers that are reproducible and sensitive enough for clinical use. AI plays a critical role in this step by processing large volumes of genomic and proteomic data to isolate specific biological signatures [31]. Within the context of drug development, these biomarkers serve as objective outcome measures in clinical trials, ensuring that the right treatment is matched to the right patient based on their unique biological profile [32].

Table 3. AI-Driven Biomarker Discovery and Validation Parameters

Parameter Category	Specific Metrics	AI Role in Evaluation
Diagnostic Accuracy	Sensitivity, Specificity, AUC-ROC	Optimizing threshold values to distinguish healthy vs. diseased states.
Predictive Power	Positive Predictive Value (PPV)	Correlating genomic signatures with specific therapeutic responses.
Reliability	Reproducibility, Coefficient of Variation	Filtering noise from high-dimensional "omics" datasets to ensure marker stability.
Prognostic Utility	Survival analysis, Progression-free intervals	Modeling disease trajectory based on longitudinal patient data.

4. Predictive Modeling and Drug Design

The design phase extends beyond the identification of active compounds to include the formulation of the final pharmaceutical product. This involves selecting appropriate delivery systems, such as tablets or solutions, and identifying compatible excipients that ensure stability and bioavailability. AI is applied at this stage to predict physical parameters including blend bulk density, flowability, and the angle of repose [33]. These predictive models also evaluate the mechanical properties of solid dosage forms, such as resistance to crushing and disintegration time, thereby optimizing the manufacturing process before physical production begins [34].

A fundamental challenge in drug design is the accurate prediction of the three-dimensional structure of target proteins. Advanced AI architectures utilize deep learning to model protein folding with high precision, which is a prerequisite for understanding how a drug will interact with its receptor [35]. These models provide insights into the molecular docking process by simulating the binding affinity and complex formation between ligands and receptors [36]. This capability is particularly useful in de-novo drug design, where novel scaffolds are generated computationally to fit specific binding pockets, bypassing the limitations of existing chemical libraries [37].

5. AI for Personalized Medicine

The transition toward personalized medicine represents a significant shift in the pharmaceutical industry, moving away from a universal treatment model to one that considers individual variability. AI assists in this transition by improving diagnostic accuracy and supporting clinical decision-making through the analysis of patient-specific data [33]. Algorithms can integrate genetic profiles, clinical histories, and lifestyle factors to predict how a specific individual will respond to a therapeutic intervention [34].

5.1. Clinical Efficiency

The ability of AI to store and examine diverse datasets reduces the financial burden associated with extensive data collection and manual analysis. This efficiency allows researchers to focus on clinical scenarios where targeted therapies can maximize effectiveness while minimizing adverse side effects [35]. The industry can develop innovative therapies that address unmet clinical needs more rapidly than traditional methods by utilizing machine learning to analyze real-time patient responses [36].



Figure 3. AI-Driven Personalized Medicine

5.2. Optimizing Therapeutic Outcomes

The rise of AI in personalized medicine facilitates the development of therapies that are optimized for specific patient cohorts. This approach not only improves the success rate of clinical trials by selecting patients more likely to benefit from a treatment but also enhances the overall safety profile of the medication [37]. In summary, the application of computational intelligence at this level provides a new framework for the delivery of healthcare, ensuring that treatments are as unique as the patients receiving them [38]

6. ADMET and Toxicity Prediction

The assessment of Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) parameters is a critical component of drug optimization, often determining the clinical viability of a candidate molecule. AI has become instrumental in evaluating how new drug candidates interact with biological systems, providing early-stage insights into safety and efficacy [39]. Data-driven models facilitate the prediction of pharmacological responses, streamlining the preclinical trial process and reducing the likelihood of late-stage failures due to unforeseen toxicities. Researchers can generate a predictive understanding of ADMET endpoints that assists in the selection of safer compounds by utilizing stored structure-activity and structure-property relationship data [40].

Table 4. ADMET Parameters Predicted by AI Models

ADMET Category	Predicted Parameter	Impact on Drug Failure Reduction
Absorption	Caco-2 Permeability, P-glycoprotein interaction	Predicts oral bioavailability and intestinal absorption hurdles.
Distribution	Blood-Brain Barrier (BBB) penetration	Identifies CNS activity or potential neurotoxicity risks.
Metabolism	CYP450 inhibition and induction	Predicts potential drug-drug interactions (DDIs).
Excretion	Renal clearance, Half-life ($t_{1/2}$)	Optimizes dosing frequency and prevents systemic accumulation.
Toxicity	hERG inhibition, Ames mutagenicity	Reduces the risk of cardiac arrhythmia and genotoxicity in clinical trials.



Figure 4. Multifactorial ADMET Modeling

AI-powered computational methods offer an efficient alternative to traditional in vivo animal testing, which is often limited by ethical concerns and high costs. Modern models are trained to identify potential adverse effects on specific organs or biological pathways by delineating complex toxicity profiles [41]. These algorithms can detect subtle patterns in chemical structures that may lead to hepatotoxicity or cardiotoxicity, enabling the prioritization of lead compounds with the most favorable safety margins [42]. The application of deep learning allows for the analysis of heterogeneous datasets to estimate chemical toxicity with a level of precision that was previously unattainable through conventional assays [43].

7. Drug Repurposing and Knowledge Graphs

Drug repurposing, the process of identifying new therapeutic indications for existing medications, is a highly efficient strategy for accelerating drug development. This approach leverages established safety data, significantly shortening development timelines and reducing associated costs [44]. AI enhances this process through the construction and analysis of knowledge graphs vast networks that integrate data from chemical databases, gene expression profiles, clinical histories, and scientific literature. These algorithms can uncover hidden opportunities for repositioning drugs to treat rare or emerging conditions by mapping the relationships between drugs, targets, and diseases [45].

Modern repurposing strategies often utilize matrix-based approaches to analyze large-scale associations between drugs and disease states. AI networks mine these relationships to identify candidates that can modulate specific disease pathways, even if the primary target of the drug was originally intended for a different condition [46]. This capability is particularly valuable in addressing emerging public health threats, where the rapid deployment of a therapeutic is necessary. The industry can respond more effectively to urgent clinical needs by prioritizing existing drugs for rapid testing through computational simulations [47].

8. Challenges and Limitations of AI Integration

While the benefits of computational intelligence are substantial, several barriers impede its universal adoption in the pharmaceutical sector. A primary concern is the reliability and reproducibility of the data used to train these models. In many instances, available datasets may be unstructured or contain biases that lead to inaccurate predictions [48]. AI systems occasionally lack the ability to distinguish between high-quality experimental data and noise, requiring continuous human oversight to ensure the validity of scientific conclusions [49].

8.1. Environmental Impact and Sustainability

A significant but often overlooked limitation of AI is the substantial environmental footprint associated with training large-scale models. The reliance on clusters of high-performance graphics processing units (GPUs) results in massive energy consumption and the generation of considerable heat. Cooling these servers often requires vast quantities of fresh water, contributing to the depletion

of local resources [50]. For example, the execution of complex interference queries can consume significant amounts of water, highlighting a conflict between technological advancement and environmental sustainability [51].

Table 5. Barriers and Challenges in AI Implementation

Challenge Type	Description	Potential Mitigation Strategy
Data Quality	Presence of "noisy" or unstructured data	Implementing rigorous data cleaning and standardization protocols.
Interpretability	The "Black Box" nature of complex neural networks	Developing Explainable AI (XAI) to clarify model decision-making.
Ethics	Patient privacy and data ownership	Utilizing federated learning to train models without moving raw data.
Infrastructure	High energy/water consumption for GPU clusters	Shifting toward "Green AI" through hardware efficiency and carbon offsets.
Regulatory	Lack of standardized validation for AI models	Collaborative frameworks between tech firms and health authorities (FDA/EMA).

8.2. Ethical and Professional Considerations

The integration of AI into drug discovery also raises ethical questions regarding data privacy and professional displacement. The requirement for large volumes of personal health information to train predictive algorithms can clash with the rights of the general public, many of whom may not be aware of how their data is being utilized [52]. Additionally, the automation of complex research processes has led to concerns regarding the potential loss of expertise as traditional roles are replaced by algorithmic workflows. Maintaining a balance between human expertise and automated efficiency remains a central challenge for the future of the industry [53].

9. Recent Trends

The trajectory of pharmaceutical research suggests that the integration of computational intelligence will move beyond simple screening to encompass more advanced, multi-modal applications. Deep learning architectures are already being utilized to extract sophisticated insights from unstructured public databases, facilitating scientific conclusions that drive de-novo drug design [54]. The ability of these networks to predict clinical trial outcomes before the commencement of human studies represents a significant opportunity to reduce the financial risks associated with phase transition failures [55].

9.1. Nanotechnology and Smart Drug Delivery

A prominent emerging trend is the convergence of AI with nanotechnology, particularly in the development of sophisticated nanocarriers. AI-driven models assist in the design of "smart" drug release systems that can detect specific physiological triggers, such as pH changes or enzymatic markers, to deliver medication exactly when and where it is needed [56]. This level of precision minimizes systemic toxicity and maximizes the therapeutic window, which is especially critical in oncology and chronic inflammatory diseases [57]. The optimization of nanocarrier physicochemical properties through machine learning ensures improved solubility and bioavailability for poorly water-soluble compounds [58].

9.2. Collaborative Ecosystems and Multidisciplinary Training

The successful implementation of AI in drug discovery requires a departure from traditional, siloed research models toward a multidisciplinary approach. Effective development now demands seamless collaboration between researchers, data scientists, clinical experts, and software engineers [59]. Consequently, there is an increasing emphasis on reforming pharmaceutical education to include technical literacy and data management competencies. Training programs are evolving to equip the next generation of professionals with the skills necessary to navigate the ethical, regulatory, and technical complexities of an automated R&D landscape [60].

9.3. Long-term Impact on Global Health Pipelines

The acceleration of the drug development pipeline through AI has profound implications for public health. By reducing the time required for lead identification and clinical recruitment tasks that once took months but can now be completed in weeks life-saving treatments reach patients significantly sooner [61]. The resources saved during the discovery phase can be reinvested into research

for rare genetic disorders and emerging infectious diseases that were previously considered commercially unviable. Ultimately, this shift toward a data-driven paradigm promises to make healthcare more accessible, affordable, and responsive to global medical needs [62].

10. Conclusion

The utilization of artificial intelligence and machine learning is transforming the methodology of drug discovery and development. These technologies have shown the capacity to enhance the efficiency, accuracy, and safety of pharmaceutical interventions by automating the analysis of vast chemical spaces and biological datasets. The transition from trial-and-error laboratory methods to predictive, data-driven simulations not only reduces the financial burden of research but also addresses the ethical concerns surrounding animal testing and human risk. While barriers such as data heterogeneity, environmental sustainability, and regulatory oversight remain, the potential for AI to provide personalized, cost-effective, and highly targeted therapies is undeniable. The evolution of these technologies will ensure that the future of drug discovery is defined by precision, speed, and a commitment to improving patient outcomes on a global scale.

References

[1] Kokudeva M, Vichev M, Naseva E, Miteva DG, Velikova T. Artificial intelligence as a tool in drug discovery and development. World J Exp Med. 2024;14(3):96042.

[2] Patel V, Shah M. Artificial intelligence and machine learning in drug discovery and development. Intell Med. 2022;2(2):134-140.

[3] Abbas MKG, Rassam A, Karamshahi F, Abunora R, Abouseada M. The role of AI in drug discovery. ChemBioChem. 2024;25(3):e202300816.

[4] Bender A, Cortes-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make drug discovery more efficient. Drug Discov Today. 2021;26(2):511-524.

[5] Rantanen J, Khinast J. The future of pharmaceutical manufacturing sciences. J Pharm Sci. 2015;104(11):3612-3638.

[6] Göller AH, Kuhnke L, Montanari F, Bonin A, Schneckener S, ter Laak A, et al. Bayer's in silico ADMET platform: a journey of machine learning over the past two decades. Drug Discov Today. 2020;25(9):1702-1716.

[7] Khan SR, Al Rijjal D, Piro A, Wheeler MB. Artificial intelligence and machine learning in drug discovery and development. Drug Discov Today. 2021;26(4):982-992.

[8] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012;40(D1):D1100-D1107.

[9] Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388-D1395.

[10] Mayr A, Klambauer G, Unterthiner T, Hochreiter S. DeepTox: Toxicity Prediction using Deep Learning. Front Environ Sci. 2016;3:80.

[11] Wu Z, Ramsundar B, Feinberg EN, Gomes J, Geniesse C, Pappu AS, et al. MoleculeNet: a benchmark for molecular machine learning. Chem Sci. 2018;9(2):513-530.

[12] Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773-780.

[13] Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80-93.

[14] Chen Z, Liu X, Hogan W, Shenkman E, Bian J. Applications of artificial intelligence in drug development: the present and future. Drug Discov Today. 2021;26(5):1256-1264.

[15] Deng J, Yang Z, Ojima I, Samaras D, Wang F. Artificial intelligence in drug discovery: applications and techniques. Brief Bioinform. 2022;23(1):bbab430.

[16] Elbadawi M, Gaisford S, Basit AW. Advanced machine-learning techniques in drug discovery. Drug Discov Today. 2021;26(3):769-777.

[17] Bender A, Cortes-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data. Drug Discov Today. 2021;26(4):1040-1052.

[18] Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-477.

[19] Lavecchia A, Di Giovanni C. Virtual screening strategies in drug discovery: a critical review. Curr Med Chem. 2013;20(23):2839-2860.

[20] Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. Statistical practice in high-throughput screening data analysis. Nat Biotechnol. 2006;24(2):167-175.

[21] Shockley KR, Gupta S, Harris SF, Lahiri SN, Peddada SD. Quality Control of Quantitative High Throughput Screening Data. Front Genet. 2019;10:387.

[22] Kraus VB. Biomarkers as drug development tools: discovery, validation, qualification and use. Nat Rev Rheumatol. 2018;14(6):354-362.

[23] Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, Zhao J, Snowdon JL. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2021;14:86-93.

[24] Schork NJ. Artificial Intelligence and Personalized Medicine. Cancer Treat Res. 2019;178:265-283.

[25] Alqahtani S. In silico ADME-Tox modeling: progress and prospects. Expert Opin Drug Metab Toxicol. 2017;13(11):1147-1158.

[26] Hessler G, Baringhaus KH. Artificial Intelligence in Drug Design. Molecules. 2018;23(10):2520.

[27] Agu PC, Obulose CN. Artificial intelligence in drug discovery and development: a review. Drug Dev Res. 2024;85(1):e22159.

[28] Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ. Machine Learning in Drug Discovery: A Review. Artif Intell Rev. 2022;55(3):1947-1999.

[29] Behei N, Tryhubchak O, Pryymak B. Development of amlodipine and enalapril combined tablets based on quality by design and artificial neural network. Pharmacia. 2022;69(3):779-789.

[30] Lombardo F, Desai PV, Arimoto R, Desino KE, Fischer H, Keefer CE, et al. In silico absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK): utility and best practices. J Med Chem. 2017;60(22):9097-9113.

[31] Yang F, Zhang Q, Ji X, Zhang Y, Li W, Peng S, Xue F. Machine Learning Applications in Drug Repurposing. Interdiscip Sci. 2022;14:15-21.

[32] Vidhya KS, Sultana A, M NK, Rangareddy H. Artificial Intelligence's Impact on Drug Discovery and Development From Bench to Bedside. Cureus. 2023;15(10):e47486.

[33] Naik N, Hameed BMZ, Shetty DK, Swain D, Shah M, Paul R, et al. Legal and Ethical Consideration in Artificial Intelligence in Healthcare: Who Takes Responsibility? Front Surg. 2022;9:862322.

[34] Karimian G, Petelos E, Evers SMAA. The ethical issues of the application of artificial intelligence in healthcare: A systematic scoping review. AI Ethics. 2022;2, 539-551.

[35] Yadav S, Singh A, Singhal R, Yadav JP. Revolutionizing drug discovery: The impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry. Intelligent Pharm. 2024;2:367-380.

[36] Dnyaneshwar K, Gaurav S, Debleena P, et al. Artificial intelligence in the pharmaceutical sector: current scene and future prospect. The future of pharmaceutical product development and research. Elsevier; 2020. p. 73-107.

[37] Ashraf FB, Akter S, Mumu SH, Islam MU, Uddin J. Bio-activity prediction of drug candidate compounds targeting SARS-Cov-2 using machine learning approaches. PLoS One. 2023;18(9):e0288053.

[38] Hasselgren C, Oprea TI. Artificial Intelligence in Drug Discovery and Development. Annu Rev Pharmacol Toxicol. 2024;64:527-550.

[39] Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589.

[40] Segler MHS, Preuss M, Waller MP. Planning chemical syntheses with deep neural networks and symbolic AI. Nature. 2018;555(7698):604-610.

[41] Stokes JM, Yang K, Swanson K, Berman WG, Cubillos-Ruiz A, Donghia NM, et al. A Deep Learning Approach to Antibiotic Discovery. Cell. 2020;180(4):688-702.

[42] Pu L, Govindaraj RG, Lemoine JM, Wu HC, Brylinski M. DeepDrug: A general graph-based deep learning framework for drug-drug interactions and drug-target interactions prediction. bioRxiv. 2019.

[43] Gawehn E, Hiss JA, Schneider G. Deep Learning in Drug Discovery. Mol Inform. 2016;35(1):3-14.

[44] Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):31-50.

[45] Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6(1):14.

[46] Zeng X, Song X, Ma T, Pan Z, Han J, Ding Y, et al. DeepDR: a network-based deep learning method for drug repositioning. Bioinformatics. 2019;35(22):4691-4698.

[47] Tanoli Z, Vähä-Koskela M, Aittokallio T. Artificial intelligence, properties and applications of knowledge graphs in drug discovery. Trends Pharmacol Sci. 2021;42(10):819-833.

[48] Ambilwade S, et al. Artificial Intelligence and Machine Learning in Drug Discovery: Transformative Applications and Interdisciplinary Integration. IJFMR. 2025;7(5):57130.

[49] Mullard A. The drug-maker's guide to the galaxy. Nature. 2017;549(7673):445-447.

[50] Strubell E, Ganesh A, McCallum A. Energy and Policy Considerations for Deep Learning in NLP. arXiv. 2019.

[51] Li P, et al. Making AI Less "Thirsty": Uncovering and Addressing the Secret Water Footprint of AI Models. arXiv. 2023.

[52] Price WN, Cohen IG. Privacy in the age of medical big data. Nat Med. 2019;25(1):37-43.

[53] Meskó B. The Role of Artificial Intelligence in Precision Medicine. Expert Rev Precis Med Drug Dev. 2017;2(5):239-241.

[54] Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence: evolutionary-algorithm-based drug design. Trends Pharmacol Sci. 2021;42(10):844-862.

[55] Harrer S, Shah P, Antony B, Hu J. Artificial Intelligence for Clinical Trial Design. Trends Pharmacol Sci. 2019;40(8):577-591.

[56] Patapoff TW, et al. Artificial intelligence and machine learning in the delivery of biopharmaceuticals. Adv Drug Deliv Rev. 2020;160:11-23.

[57] Shinde SS, et al. Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy. Front Med Technol. 2022;4:1067144.

[58] Wang Q, et al. AI Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. Pharmaceutics. 2023;15(10):2459.

[59] Jiménez-Luna J, Grisoni F, Schneider G. Drug discovery with explainable artificial intelligence. Nat Mach Intell. 2020;2(10):573-584.

[60] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.

[61] Smalley E. AI-powered drug discovery captures pharma interest. Nat Biotechnol. 2017;35(7):604-605.

[62] Schwalbe N, Wahl B. Artificial intelligence and the future of global health. Lancet. 2020;395(10236):1579-1586.